Navigation Links
Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
Date:4/22/2008

Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate Study

PINE BROOK, N.J., April 22 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced pivotal animal efficacy results of Anthim(TM), a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.

Elusys' Anthim is designed as a "just in time" anthrax therapeutic that can be administered by a single, rapid intramuscular injection and has the potential to provide quick protection against the lethal effects of anthrax toxin.

In this study, primates were infected with a highly lethal dose of aerosolized anthrax spores and observed for 60 days. A single IM dose of Anthim provided significant protection (75% survival) when administered at the onset of clinical symptoms of disease (24 hr. post exposure). These results are consistent with a recent rabbit study that showed significant survival of animals treated 24 hours after infection when bacteremia was present.

Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented on the results, "Anthim continues to demonstrate life-saving potential when given in a single, low IM dose after clinical symptoms of infection are present. In earlier animal studies, Anthim provided 100 percent protection when given prior to an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our Phase I human safety study demonstrated Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin."

Dr. Posillico continued, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited because the results of our studies show that rapid IM treatment w
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
2. Special coating greatly improves solar cell performance
3. Method to deliver molecules within embryonic stem cells improves differentiation
4. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
5. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
8. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
9. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...LAFAYETTE, Ind. - A new generation of ultrasmall t...tiny structures called semiconducting nanowires ar...rchers at IBM, Purdue University and the Universit...s have learned how to create nanowires with layers...t the atomic level, which is a critical requiremen...
(Date:11/25/2009)... MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma to...to its Board of Directors. Dr. Moldt will replace ...the Company,s Board. The number of Board members r...y pleased to welcome Peter Moldt to the board and ... guidance as Cytochroma continues to make progress...
(Date:11/24/2009)..., HOUSTON, Nov. 24 IE... electrical and communications systems and service...arkets, announced today that its commercial busine...n Torcon JV to install the electrical systems for ...ility at the U.S. Army Medical Research Institute ...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 ...asdaq: DCGN ) today announced that it has received...in the company,s common stock will be,suspended as...led with the,Securities and Exchange Commission, w...g on Nasdaq, unless the company files an appeal to...
Breaking Biology Technology:Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...arch 14 ,Renovis, Inc. (Nasdaq: RNVS ), a biophar...velopment of drugs for major medical needs in the ...oday announced financial results,for the fourth qu...for the fourth quarter and the year ended December...ctively, compared to $2.2 million and,$10.4 millio...
... Diagnostics,Incorporated (NYSE: DGX ), the natio...ation and services, announced that it is scheduled...lobal Healthcare Conference on,Wednesday, March 19...rida.,The Quest Diagnostics presentation is schedu...entation will be webcast live during the conferenc...
... Inc. (Nasdaq:,NUVA), a medical device company foc...ve surgical treatments for the spine, announced to...nd Chief Financial Officer,is scheduled to present...lthcare Conference at the Loews Miami Beach Hotel ... 10:15 a.m. ET., A live Web cast of the presentat...
Other Biology Technology:Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 3Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 4Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 5Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 6Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 7Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3
(Date:11/24/2009)...ened and flabby arteries from collapsing have been...nts are no longer needed -- once the arteries are ... doctors had no choice but to leave them in place....,s Department of Biomedical Engineering has develo...es drugs where they,re needed, then dissolves. , ...
(Date:11/24/2009)...ORK (November 24, 2009) -- The Wildlife Conservati...g that the last remaining population of Siberian t... rising tide of poaching and habitat loss. , ...ian officials of what needs to be done to protect ... , The report was released by the Si...
(Date:11/24/2009)...ber 24, 2009) New research on bacterial communiti...veals predictable temporal patterns, suggesting th...rs for monitoring climate change in the polar regi...dings of the National Academy of Sciences Early E...x rivers shifted synchronously over time, correlat...
Breaking Biology News(10 mins):A coating for life 2Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 13588 1SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 13588 2Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 1Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 2Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 3Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 4For Short Kids No Lack of Self Esteem 54617 1For Short Kids No Lack of Self Esteem 54617 2For Short Kids No Lack of Self Esteem 54617 3
...most common form of lung cancer may begin in a gro... researchers from the Howard Hughes Medical Instit...isolated a novel type of lung cell that can divide... specialized kinds of cells deep in the lung. Thei...umor development, the stem cell appears to be the ...
...archers working with rats have zeroed in on the br...es to the impulsive behavior seen in users of coca...me circuitry has been implicated in such disorders...stress disorder, wrote the researchers. , Yukiori ...tsburgh described their findings in the July 21, 2...
...mbination of the drugs ribavirin and interferon is... interferon alone, but it also increases the risk ...iew of recent evidence. , "Adding ribavirin to any...ment of choice for patients with hepatitis C," con...gen University Hospital. , However, the authors c...
Other Biology News:Most common lung cancers may begin in newly discovered cells 2Most common lung cancers may begin in newly discovered cells 3Most common lung cancers may begin in newly discovered cells 4New clue to cocaine addicts' quirky behavior 2Hepatitis C responds best to combo of ribavirin and interferon, study concludes 2Hepatitis C responds best to combo of ribavirin and interferon, study concludes 3
PCP ELISA Kit, Single from Bio-Quant Inc.
Cotinine ELISA Kit, Single from Bio-Quant Inc.
...d IHC Protocol Development ,Antibody Titer and Opt...nimal or Human Cells and Tissues ,Double Antibody ...e Phosphatase, Immunogold, and Fluorescent detecti...otein Localization in Transgenic Animals ,Hundreds...
Detection Reagents; Design; Development and Application from QualTek Molecular Laboratories
Biology Products: